Slug promoted vasculogenic mimicry in hepatocellular carcinoma

Journal of Cellular and Molecular Medicine

Volumn 17, Issue 8, 2013, Pages 1038-1047

  Sun, Dan ^a   Sun, Baocun ^a   Liu, Tieju ^a   Zhao, Xiulan ^a   Che, Na ^a   Gu, Qiang ^a   Dong, Xueyi ^a   Yao, Zhi ^a   Li, Rui ^a   Li, Jing ^a   Chi, Jiadong ^a   Sun, Ran ^a  

^a TIANJIN MEDICAL UNIVERSITY   (China)

Author keywords

Cancer stem cells; Hepatocellular carcinoma; Slug; Vasculogenic mimicry

Indexed keywords

SNAIL FAMILY TRANSCRIPTION FACTORS; TRANSCRIPTION FACTOR;

ANIMAL; ARTICLE; CANCER STEM CELL; DRUG SCREENING; EPITHELIAL MESENCHYMAL TRANSITION; HUMAN; LIVER CELL CARCINOMA; LIVER TUMOR; METABOLISM; MOUSE; NEOVASCULARIZATION (PATHOLOGY); PATHOLOGY; PHENOTYPE; SLUG; TUMOR CELL LINE; VASCULARIZATION; VASCULOGENIC MIMICRY;

CANCER STEM CELLS; HEPATOCELLULAR CARCINOMA; SLUG; VASCULOGENIC MIMICRY;

ANIMALS; CARCINOMA, HEPATOCELLULAR; CELL LINE, TUMOR; EPITHELIAL-MESENCHYMAL TRANSITION; HUMANS; LIVER NEOPLASMS; MICE; NEOPLASTIC STEM CELLS; NEOVASCULARIZATION, PATHOLOGIC; PHENOTYPE; TRANSCRIPTION FACTORS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84888199808     PISSN: 15821838     EISSN: None     Source Type: Journal    
DOI: 10.1111/jcmm.12087     Document Type: Article

References (37)

1. Dome B, Hendrix MJ, Paku S, et al. Alternative vascularization mechanisms in cancer: pathology and therapeutic implications. Am J Pathol. 2007; 170: 1-15.
2. Sun B, Zhang S, Zhang D, et al. Vasculogenic mimicry is associated with high tumor grade, invasion and metastasis, and short survival in patients with hepatocellular carcinoma. Oncol Rep. 2006; 16: 693-8.
3. Kirschmann DA, Seftor EA, Hardy KM, et al. Molecular pathways: vasculogenic mimicry in tumor cells: diagnostic and therapeutic implications. Clin Cancer Res. 2012; 18: 2726-32.
4. Wang SY, Yu L, Ling GQ, et al. Vasculogenic mimicry and its clinical significance in medulloblastoma. Cancer Biol Ther. 2012; 13: 341-8.
5. Sun T, Sun BC, Zhao XL, et al. Promotion of tumor cell metastasis and vasculogenic mimicry by way of transcription coactivation by Bcl-2 and Twist1: a study of hepatocellular carcinoma. Hepatology. 2011; 54: 1690-706.
6. Sun T, Zhao N, Zhao XL, et al. Expression and functional significance of Twist1 in hepatocellular carcinoma: its role in vasculogenic mimicry. Hepatology. 2010; 51: 545-56.
7. Mani SA, Guo W, Liao MJ, et al. The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell. 2008; 133: 704-15.
8. Kasimir-Bauer S, Hoffmann O, Wallwiener D, et al. Expression of stem cell and epithelial-mesenchymal transition markers in primary breast cancer patients with circulating tumor cells. Breast Cancer Res. 2012; 14: R15.
9. Sarrio D, Franklin CK, Mackay A, et al. Epithelial and mesenchymal subpopulations within normal basal breast cell lines exhibit distinct stem cell/progenitor properties. Stem Cells. 2012; 30: 292-303.
10. Casas E, Kim J, Bendesky A, et al. Snail2 is an essential mediator of Twist1-induced epithelial mesenchymal transition and metastasis. Cancer Res. 2011; 71: 245-54.
11. Bao S, Wu Q, Sathornsumetee S, et al. Stem cell-like glioma cells promote tumor angiogenesis through vascular endothelial growth factor. Cancer Res. 2006; 66: 7843-8.
12. - phenotype. BMC Cancer. 2010; 10: 411.
13. Zhu LF, Hu Y, Yang CC, et al. Snail overexpression induces an epithelial to mesenchymal transition and cancer stem cell-like properties in SCC9 cells. Lab Invest. 2012; 92: 744-52.
14. Kurrey NK, Jalgaonkar SP, Joglekar AV, et al. Snail and slug mediate radioresistance and chemoresistance by antagonizing p53-mediated apoptosis and acquiring a stem-like phenotype in ovarian cancer cells. Stem Cells. 2009; 27: 2059-68.
15. Bittner M, Meltzer P, Chen Y, et al. Molecular classification of cutaneous malignant melanoma by gene expression profiling. Nature. 2000; 406: 536-40.
16. Liu TJ, Sun BC, Zhao XL, et al. CD133 + cells with cancer stem cell characteristics associates with vasculogenic mimicry in triple-negative breast cancer. Oncogene. 2013; 32: 544-53.
17. Hotz B, Arndt M, Dullat S, et al. Epithelial to mesenchymal transition: expression of the regulators snail, slug, and twist in pancreatic cancer. Clin Cancer Res. 2007; 13: 4769-76.
18. Raimondi C, Gianni W, Cortesi E, et al. Cancer stem cells and epithelial-mesenchymal transition: revisiting minimal residual disease. Curr Cancer Drug Targets. 2010; 10: 496-508.
19. Battula VL, Evans KW, Hollier BG, et al. Epithelial-mesenchymal transition-derived cells exhibit multilineage differentiation potential similar to mesenchymal stem cells. Stem Cells. 2010; 28: 1435-45.
20. Singh A, Settleman J. EMT, cancer stem cells and drug resistance: an emerging axis of evil in the war on cancer. Oncogene. 2010; 29: 4741-51.
21. Beck B, Driessens G, Goossens S, et al. A vascular niche and a VEGF-Nrp1 loop regulate the initiation and stemness of skin tumours. Nature. 2011; 478: 399-403.
22. Cao Y. Off-tumor target-beneficial site for antiangiogenic cancer therapy? Nat Rev Clin Oncol. 2010; 7: 604-8.
23. Xue Y, Lim S, Yang Y, et al. PDGF-BB modulates hematopoiesis and tumor angiogenesis by inducing erythropoietin production in stromal cells. Nat Med. 2012; 18: 100-10.
24. Cao Y, Arbiser J, D'Amato RJ, et al. Forty-year journey of angiogenesis translational research. Sci Transl Med. 2011; 3: 114rv3.
25. Cao Y, Langer R. Optimizing the delivery of cancer drugs that block angiogenesis. Sci Transl Med. 2010; 2: 15.
26. Cao R, Xue Y, Hedlund EM, et al. VEGFR1-mediated pericyte ablation links VEGF and PlGF to cancer-associated retinopathy. Proc Natl Acad Sci USA. 2010; 107: 856-61.
27. Cao R, Ji H, Feng N, et al. Collaborative interplay between FGF-2 and VEGF-C promotes lymphangiogenesis and metastasis. Proc Natl Acad Sci USA. 2012; 109: 15894-9.
28. Pirozzi G, Tirino V, Camerlingo R, et al. Epithelial to mesenchymal transition by TGFbeta-1 induction increases stemness characteristics in primary non small cell lung cancer cell line. PLoS ONE. 2011; 6: e21548.
29. Cao L, Shao M, Schilder J, et al. Tissue transglutaminase links TGF-beta, epithelial to mesenchymal transition and a stem cell phenotype in ovarian cancer. Oncogene. 2012; 31: 2521-34.
30. Kong D, Li Y, Wang Z, et al. Cancer stem cells and epithelial-to-mesenchymal transition (EMT)-phenotypic cells: are they cousins or twins? Cancers. 2011; 3: 716-29.
31. Shen R, Ye Y, Chen L, et al. Precancerous stem cells can serve as tumor vasculogenic progenitors. PLoS ONE. 2008; 3: e1652.
32. Wang R, Chadalavada K, Wilshire J, et al. Glioblastoma stem-like cells give rise to tumour endothelium. Nature. 2010; 468: 829-33.
33. Bjerkvig R, Johansson M, Miletic H, et al. Cancer stem cells and angiogenesis. Semin Cancer Biol. 2009; 19: 279-84.
34. Dong J, Zhao Y, Huang Q, et al. Glioma stem/progenitor cells contribute to neovascularization via transdifferentiation. Stem Cell Rev. 2011; 7: 141-52.
35. Monzani E, La Porta CA. Targeting cancer stem cells to modulate alternative vascularization mechanisms. Stem Cell Rev. 2008; 4: 51-6.
36. Salmaggi A, Boiardi A, Gelati M, et al. Glioblastoma-derived tumorospheres identify a population of tumor stem-like cells with angiogenic potential and enhanced multidrug resistance phenotype. Glia. 2006; 54: 850-60.
37. Ricci-Vitiani L, Pallini R, Biffoni M, et al. Tumour vascularization via endothelial differentiation of glioblastoma stem-like cells. Nature. 2010; 468: 824-8.